Gilliland Jeter Wealth Management LLC Takes Position in Edwards Lifesciences Co. (NYSE:EW)

Gilliland Jeter Wealth Management LLC purchased a new stake in shares of Edwards Lifesciences Co. (NYSE:EW) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 5,725 shares of the medical research company’s stock, valued at approximately $437,000.

Several other institutional investors have also recently made changes to their positions in EW. Headlands Technologies LLC increased its holdings in Edwards Lifesciences by 115.4% in the 4th quarter. Headlands Technologies LLC now owns 5,362 shares of the medical research company’s stock valued at $409,000 after purchasing an additional 2,873 shares during the last quarter. Callan Capital LLC acquired a new stake in Edwards Lifesciences in the 4th quarter valued at approximately $2,116,000. Bahl & Gaynor Inc. acquired a new stake in Edwards Lifesciences in the 4th quarter valued at approximately $404,000. Bank Julius Baer & Co. Ltd Zurich increased its holdings in Edwards Lifesciences by 0.3% in the 4th quarter. Bank Julius Baer & Co. Ltd Zurich now owns 794,611 shares of the medical research company’s stock valued at $60,589,000 after purchasing an additional 2,000 shares during the last quarter. Finally, Sandhill Capital Partners LLC increased its holdings in Edwards Lifesciences by 3.7% in the 4th quarter. Sandhill Capital Partners LLC now owns 24,972 shares of the medical research company’s stock valued at $1,904,000 after purchasing an additional 900 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on EW shares. Citigroup lifted their target price on shares of Edwards Lifesciences from $90.00 to $98.00 and gave the company a “neutral” rating in a report on Wednesday, April 3rd. Morgan Stanley boosted their price target on shares of Edwards Lifesciences from $95.00 to $103.00 and gave the stock an “overweight” rating in a research note on Thursday, March 21st. Mizuho boosted their price target on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the stock a “buy” rating in a research note on Thursday, April 11th. Oppenheimer boosted their price target on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the stock an “outperform” rating in a research note on Monday, March 18th. Finally, Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating in a research note on Thursday, March 7th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $93.33.

Insiders Place Their Bets

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,255 shares of the company’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $78.29, for a total transaction of $567,993.95. Following the transaction, the chief financial officer now directly owns 19,248 shares in the company, valued at $1,506,925.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, CFO Scott B. Ullem sold 7,255 shares of the stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $78.29, for a total value of $567,993.95. Following the sale, the chief financial officer now directly owns 19,248 shares in the company, valued at $1,506,925.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Heisz Leslie Stone sold 7,056 shares of the stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $86.45, for a total transaction of $609,991.20. Following the completion of the sale, the director now owns 26,980 shares in the company, valued at $2,332,421. The disclosure for this sale can be found here. Over the last three months, insiders have sold 194,004 shares of company stock worth $17,166,254. 1.29% of the stock is owned by company insiders.

Edwards Lifesciences Stock Performance

Shares of NYSE:EW traded down $1.58 on Friday, reaching $86.43. The company’s stock had a trading volume of 4,979,943 shares, compared to its average volume of 2,883,164. The stock’s 50-day moving average is $90.28 and its two-hundred day moving average is $78.85. Edwards Lifesciences Co. has a 52-week low of $60.57 and a 52-week high of $96.12. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.38 and a quick ratio of 2.40. The stock has a market capitalization of $52.02 billion, a P/E ratio of 37.25, a PEG ratio of 4.36 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 23.34%. The business had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.58 billion. As a group, sell-side analysts forecast that Edwards Lifesciences Co. will post 2.76 EPS for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.